Thetford Mines / TheNewswire / March 9, 2018 - KDA Group Inc. (TSXV: KDA) ("KDA Group" or the "Corporation") announced today that it has accepted the resignation of its Chief Financial Officer, Mr. Bruno Dumais, effective immediately. Mr. Dumais is leaving the Corporation to pursue other interests. In the interim, Mr. Michael Kinley, Chairman of the Audit Committee, will assume the responsibilities of Chief Financial Officer. The Corporation will commence its search for a new CFO immediately.
Marc Lemieux, Chief Executive Officer of the Corporation commented, "I would like to thank Bruno for his contributions to KDA Group. He played a critical role in our recently completed acquisitions as well as managing our liquidity during last year's challenging conditions. The Board and I wish him success in his future endeavours."
KDA Group is pleased to announce the appointments of Mrs. Annie Mercier as Finance Director of the Corporation, and Mr. Julien Berthiaume as Commercial Strategy Director of its subsidiary Pharmapar Inc. ("Pharmapar"), effective immediately.
Prior to joining KDA Group, Mrs. Mercier held financial management positions in various industries over her more than 15-year career.
Mr. Berthiaume, for his part, has held various management positions over his career of more than 20 years. His experience ranges from consumer goods to the pharmaceutical industry, including senior executive positions at Sandoz Canada.
"We are absolutely delighted to welcome both Annie, as Finance Director of KDA Group and Julien as Commercial Strategy Director of Pharmapar. They are experienced executives, passionate about the pharmaceutical industry, who understand the challenges and the needs of our customers. Their dynamism, combined with their experience and leadership will undoubtedly benefit Pharmapar and KDA Group, as well as all of our clients," said Marc Lemieux, Chief Executive Officer of KDA Group.
About KDA Group
KDA Group is a leading solution and service provider to the pharmaceutical market for the distribution of generic drugs and specialized solutions. Today it is a respected name for quality and expertise among pharmacists. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.
- 30 -
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Chief Executive Officer